FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.06-5798fje.
This Article
Right arrow Abstract Freely available
Right arrow Summary
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
fj.06-5798fjev1
20/13/2363    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bultinck, J.
Right arrow Articles by Cauwels, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bultinck, J.
Right arrow Articles by Cauwels, A.
(The FASEB Journal. 2006;20:2363-2365.)
© 2006 FASEB

Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock

Jennyfer Bultinck*, Patrick Sips*, Luc Vakaet{dagger}, Peter Brouckaert* and Anje Cauwels*,1

* Department for Molecular Biomedical Research, Ghent University and VIB, Ghent, Belgium; and

{dagger} Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium

1Correspondence: Department for Molecular Biomedical Research, Ghent University/VIB, Technologiepark 927, Ghent 9052, Belgium. E-mail: anje.cauwels{at}dmbr.ugent.be

ABSTRACT

Septic shock is the leading cause of death in noncoronary intensive care units and the 10th leading cause of death overall. Several lines of evidence support an important role for the vasodilator NO in hypotension, a hallmark of septic shock. However, NO may also positively or negatively regulate inflammation, apoptosis, and oxidative stress. These dual effects of NO may relate to its isoform specific production but also to differences in cellular and/or temporal expression. Via bone marrow transplantations, we examined the contribution of hematopoietic cells to the dramatically elevated NO levels seen in (septic) shock. Surprisingly, hematopoietic cells are not responsible at all for the production of circulating NO after systemic tumor necrosis factor or lipopolysaccharide challenge and contribute only marginally in a bacteremic (Salmonella) model of septic shock. Immunohistochemistry identified the nonhematopoietic sources of NO as hepatocytes, paneth cells, and intestinal and renal epithelial cells. In contrast, during granulomatous Bacillus Calmette-Guérin inflammation, the hematopoietic cell population represents the sole source of systemic NO. These mouse data demonstrate that, in contrast to the general conjecture, the dramatically elevated levels of NO during (septic) shock are not produced by hematopoietic cells such as monocytes/macrophages but rather by parenchymal cells in liver, kidney and gut.—Bultinck, J., Sips, P., Vakaet, L., Brouckaert, P., Cauwels, A. Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock


Key Words: inflammation • inducible NOS • bone marrow transplantation

NOIS A FREE RADICAL with pleiotropic functions in a wide variety of physiological systems. In the cardiovascular system, NO exerts vasodilatory, antiadhesive and antiproliferative effects (1) . Three different isoforms of NO synthase (NOS) exist: endothelial (e), neuronal (n), and inducible (i) NOS. As opposed to the constitutive enzymes eNOS and nNOS, iNOS is synthesized de novo during inflammation, is Ca2+/calmodulin-independent, and produces large amounts of NO over prolonged periods of time (2) . NO derived from iNOS is essential for the survival of the host during infection, but the exact function(s) of induced NO in inflammatory settings like sepsis, systemic TNF treatment, inflammatory bowel disease, and rheumatoid arthritis remain unclear (3 4 5) .

TNF is a central regulator of immunity and inflammation. Systemic TNF treatment provokes a lethal shock syndrome, in which cardiovascular collapse is centrally orchestrated by NO (6) . TNF interacts with TNF-R1 and TNF-R2, with most TNF activities being mediated by TNF-R1 (7 , 8) . We have previously reported that cardiovascular failure and mortality after TNF treatment can be prevented by inhibition of soluble guanylate cyclase activation, the prototype receptor for NO (9) . However, iNOS-derived NO also exerts protective effects by tempering TNF-induced oxidative stress (10) .

Sepsis and septic shock are systemic inflammatory response syndromes resulting from and complicating an infection. They are the leading cause of death in noncoronary intensive care units and the incidence continues to increase (11) . LPS, a constituent of the outer membrane of Gram-negative bacteria, mimics most of the septic effects and is widely used as an experimental model for septic shock (12) . NO plays a controversial role in the pathophysiology of septic shock. Since it causes hemodynamic instabilities and tissue damage (13 14 15 16) , NO may be considered detrimental to the host. However, NO may also confer protection to the host as an anti-inflammatory, antioxidant, and/or antiapoptotic agent (17) . This ambiguity became remarkably clear when a clinical trial using NOS inhibitors in septic shock patients had to be prematurely terminated because of increased mortality associated with treatment, despite beneficial effects on systemic blood pressure (18 , 19) . Several studies alsosuggest a variable role for iNOS depending on its cellular location and temporal expression (20 21 22 23 24) .

Despite the fact that a multitude of cell types, both of hematopoietic and nonhematopoietic origin, have the ability to express iNOS in vitro as well as in vivo (25 26 27 28 29 30) , it is still generally believed that macrophages, or immune cells in general, are the principle source of high systemic NO levels during septic shock. To determine the actual in vivo contribution of hematopoietic cells in systemic NO production during inflammatory or septic shock, we performed bone marrow transplantation (BMT) experiments between wild-type (WT) and iNOS- or TNF-R1-deficient mice. Surprisingly, hematopoietic cells did not contribute to the production of systemic NO after TNF or LPS challenge and only minimally during Salmonella infection. In line with this, the major iNOS-expressing cells in these three shock models were identified as hepatocytes, paneth cells, and epithelial cells of the gastrointestinal tract and the kidney. In contrast, during BCG infection, a granulomatous inflammatory reaction model characterized by the formation of granulomas in reticulo-endothelial organs, hematopoietic cells were clearly the only source of systemic NO.

MATERIALS AND METHODS

Laboratory Animals
Female C57BL/6 mice were purchased from Janvier (France). iNOS-deficient (31 ; Jackson Laboratories) and TNF-R1-deficient mice (8) on a B6 background were bred as homozygotes in our facilities. All mice were housed in temperature-controlled, air-conditioned facilities with 14/10 h light/dark cycles, food and water ad libitum, and were used at 7–12 wk at the beginning of the experiment. All experiments were performed according to the guidelines of the animal ethics committee from the Ghent University, Belgium.

Reagents
Recombinant murine TNF was produced in E. coli and purified to homogeneity. Two different batches were used. For the kinetic and BMT experiments, specific activity was 1.6 x 108 IU/mg. In all other experiments, TNF had a specific activity of 1.2 x 108 IU/mg. The endotoxin content was <0.02 ng/mg (Limulus amoebocyte lysate assay, NODIA BV, Belgium). E. coli (serotype 0111:B4) and S. abortus equi LPS were purchased from Sigma (St. Louis, MO, USA). Live BCG organisms were provided by the Institut Pasteur du Brabant (Brussels, Belgium) and the virulent S. enteritidis bacteria by the Ghent University Hospital (Ghent, Belgium).

Injections and bacterial inoculations
Injections of TNF, LPS, and BCG were done intravenously in 0.2 ml. Salmonella bacteria were grown at 37°C in Luria-Bertani (Difco, Detroit, MI, USA) and inoculated intraperitoneally in 0.2 ml PBS. The number of viable bacteria was checked by dilution and pour plating.

Blood Collection, IL-6, and NOx Measurement
Blood was collected via cardiac puncture, allowed to clot at 37°C, and centrifuged to obtain serum. Interleukin (IL)-6 was measured using a 7TD1 bioassay (32) . NO2 + NO3 (NOx) concentration was determined using Griess reagent (33) as described before (9) .

BMT
Recipient mice at 9–12 wk of age were lethally irradiated (9 Gy for iNOS–/– and 10 Gy for WT or TNF-R1–/–) and the next day injected intravenously with 107 BM cells isolated from femur and tibia of donor mice. The mice were left to recover for at least 8 wk. As a control for sufficient irradiation, one mouse was not reconstituted and died within 2 wk. Four days before irradiation, mice were housed in sterile cages. The drinking water was sterile, containing 0.2% neomycin sulfate.

Control polymerase chain reaction for BMT
Successful reconstitution of the hematopoietic lineage after irradiation and BMT was monitored by polymerase chain reaction (PCR). Mice were bled for DNA preparation from the WBC population, using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). The following primers were used: 5'-CCTCAGAGTCCTTCATGAAGCACAATGC-3' and 5'-TGTTGAAGGCGTAGCTGAACAAGGTGG-3' (wild-type iNOS); 5'-TAGGTCTCTAAGTCTGTGGACTTGGACC-3' and 5'-ACTGCTCGACATTGGGTGGAAACATTCC-3' (iNOS–/–, ref 31 ); 5'-TGCTGATGGGGATACATCCAT-3' and 5'-CTTTGTGGCACTTGGTGCAGC-3' (wild-type TNF-R1); and 5'-CAACGCTATGTCCTGATAGCGGTCC-3' and 5'-CGTGTTCCGGCTGTCAGCGCAAGG-3' (TNF-R1–/–). PCR amplification was conducted for 5 min at 95°C, followed by 39 cycles of 1 min at 95°C, 1 min at 69°C (wild-type iNOS) or at 60°C (i NOS–/–), 1.5 min at 72°C, and finally 10 min at 72°C; or 4 min at 94°C, followed by 34 cycles of 45 s at 94°C, 45 s at 57°C, 30 s at 72°C, and finally 7 min at 72°C (wild-type TNF-R1); or 4 min at 94°C, followed by 34 cycles of 1 min at 94°C, 1 min at 55°C, 3 min at 72°C, and finally 7 min at 72°C (TNF-R1–/–).

Real time-Quantitative PCR
Total RNA was extracted from 30 mg tissue with the RNeasy Protect Mini Kit (Qiagen, Valencia, CA). During RNA purification, an on-column DNase digestion removed any residual genomic DNA. 1 µg of total RNA (measured spectrophotometrically) was reverse transcribed with random hexamers into cDNA using the Superscript First-Strand Synthesis System for reverse transcriptase (RT)-polymerase chain reaction (Invitrogen Life Technologies, Carlsbad, CA). The cDNA was diluted 40-fold [for iNOS, GAPDH, and hydroxymethylbilane synthase (HMBS) ]or 400-fold [for ribosomal protein l13a (Rpl13a)] before PCR amplifications, which were performed in a total volume of 25 µl, containing 10 µl cDNA sample, 10 µl qPCR Core Kit for SYBR Green I mix (Eurogentec, Seraing, Belgium) and 5 µl primer mix (for GAPDH 125 nM, for iNOS, HMBS, and Rpl13a 300 nM of each primer). A nontemplate control was always run and all PCR amplifications were performed in triplicate under the following conditions: 2 min at 50°C and 10 min at 95°C, followed by a total of 40 two-temperature cycles (15 s at 95°C and 1 min at 60°C). After amplification, a melting curve was acquired by heating the product to 95°C, cooling it to 60°C, and keeping it there for 15 s and then slowly heating it to 95°C. Fluorescence was measured through the slow heating phase. Melting curves were used to determine the specificity of PCR products.

The following forward and reverse murine primers were used: 5'-CAGCTGGGCTGTACAAACCTT-3' and 5'-CATTGGAAGTGAAGCGTTTCG-3' (inducible NOS); 5'-GAAACTCTGCTTCGCTGCATT-3' and 5'-TGCCCATCTTTCATCACTGTATG-3' (HMBS); 5'-CCTGCTGCTCTCAAGGTTGTT-3' and 5'-TGGTTGTCACTGCCTGGTACT T-3' (Rpl13a); and 5'-ACCATCTTCCAGGAGCGAGAC-3' and 5'-GCCTTCTCCATGGTGGTGAA-3' (GAPDH). Relative RNA levels are presented, normalized against the mean of three reference housekeeping genes: HMBS, Rpl13a, and GAPDH.

WB Analysis
Frozen organs were homogenized and cleared by centrifugation; 25 µg of total protein was fractionated by SDS-PAGE, transferred to nitrocellulose, and incubated with a rabbit anti-inducible NOS antibody (Ab; Transduction Laboratories, Lexington, KY, 1/6000). Immune complexes were detected using a horseradish peroxidase-coupled anti-rabbit IgG Ab (Cell Signaling Technology, Beverly, MA) and the enhanced chemiluminescence (ECL) method (Western Lightning Chemiluminescence Reagent plus, PerkinElmer Life Science, Boston, MA).

Tissue Embedding, Sectioning, and Staining
Organs were fixed in 4% paraformaldehyde. After dehydration and paraffin embedding, 4 µm sections were prepared and incubated for 3 h at 37°C with rabbit anti-iNOS Ab (1/200, Chemicon, Temecula, CA; 1/500, Transduction Laboratories, Lexington, KY; 1/200, Santa Cruz Biotechnology, Santa Cruz, CA). Envision was used for 40 min at RT as secondary Ab, and visualization was done with an aminoethylcarbazole substrate (both from DAKO, Carpinteria, CA).

Statistics
Significance of IL-6 and NOx changes was examined using a one-way ANOVA Bonferroni test (with comparison of all pairs). NOx levels were compared with the corresponding treatment in the WT to WT group, except for the Salmonella infection experiment, where it is indicated separately.

RESULTS

Kinetics of NOx production after different inflammatory stimuli
To verify the optimal time point for measurement of systemic NOx (=NO2+NO3=biologically stable breakdown products of NO), kinetic studies were performed. As shown in Fig. 1 A, NOx release in circulation was significantly detectable from 4 h after lethal TNF or LPS challenge on and further increased until 12 or 16 h, respectively. Three independent studies gave identical kinetic patterns. Hence, we decided to determine systemic NOx levels 8 h after TNF or LPS treatment in all future experiments, considering the absence of mortality and the significant amounts of NOx produced at that time point. For the bacteremic model of septic shock, mice were inoculated intraperitoneally with 800 cfu of S. enteritidis bacteria, causing death from 36 h on (not shown). Systemic NOx was detectable after 6 to 12 h postinfection, reaching a plateau 12–20 h after inoculation. However, in contrast to TNF or LPS, systemic NOx levels dropped again afterward, before the onset of lethality (Fig. 1A ). Because the kinetics of NOx production varied considerably between different experiments, we followed systemic NOx levels at various time points in all subsequent Salmonella experiments. In BCG-infected mice, we determined NOx levels 2 h after challenge, since mortality occurred 2 to 3 h after TNF treatment due to hypersensitivity of the BCG-infected mice (34) .


Figure 1
View larger version (32K):
[in this window]
[in a new window]
 
Figure 1. A) TNF-, LPS-, or Salmonella-induced systemic NOx production. WT mice were injected iv with PBS, 15 µg TNF, or 300 µg S. abortus equi LPS, or ip with 800 cfu S. enteritidis. Numbers within figure are number of mice that survived/total number of mice, at indicated time points. Only surviving mice were bled and used for NOx measurement. ***P < 0.001, **P < 0.01, *P < 0.05, as compared with PBS. B) NOx levels in serum of TNF- or LPS-treated WT, iNOS–/– and BMT mice. Mice were injected iv with PBS, 12.5 µg TNF, 300 µg E. coli LPS or 150 µg S. abortus equi LPS. Serum NOx levels were determined 8 h later. ***P < 0.001, as compared with corresponding treatment in WT to WT group. Insert: PCR reactions, specific for WT or deficient iNOS allele, were performed on WBC DNA of BMT mice. I: WT to WT, II: iNOS–/– to WT, III: WT to iNOS–/–, IV: iNOS–/– to iNOS–/–, M: marker. C) NOx levels in serum of TNF-treated WT, TNF-R1–/– and BMT mice. Mice were injected iv with PBS or 12.5 µg TNF. Systemic NOx was determined 8 h after treatment. Plotted are means ± SD; numbers above bars are number of mice used. ***P < 0.001 as compared with corresponding treatment in WT to WT group.

Parenchymal cells are the only source of systemic NOx during TNF- or LPS-induced shock
To investigate the involvement of the hematopoietic cell population in systemic NOx production after TNF or LPS, we performed BMT experiments. Irradiated iNOS–/– mice were reconstituted with WT BM cells and vice versa. As a control, WT and iNOS–/– mice were, after irradiation, transplanted with homologous BM cells. To check the BMT effectiveness, the genotype of circulating WBCs was determined. As shown in Fig. 1B (insert), virtually all the hematopoietic cells of the reconstituted mice were of the donor genotype. Three days later, the mice were injected intravenously with lethal doses of TNF, E. coli or S. abortus equi LPS. Systemic IL-6 levels 8 h after challenge were comparable, indicating an equivalent inflammatory reaction in all control and BM-chimeric mice (not shown). TNF or LPS did not induce any detectable NOx in circulation of iNOS–/– mice with an iNOS+/+ hematopoietic cell population, while they clearly did in mice that express iNOS in every cell but the hematopoietic cells (Fig. 1B ). Therefore, in TNF- or LPS-challenged mice, parenchymal cells are fully responsible for the systemic NOx production. For TNF, we confirmed this result with a BMT experiment between WT and TNF-R1–/– mice (Fig. 1C ).

Also in a bacteremic model of septic shock, parenchymal cells are the primary source of systemic NOx
The lack of involvement of hematopoietic cells in TNF- or LPS-induced systemic NOx production was unexpected, considering the importance of these cells in immunity and inflammation and their in vitro ability to produce massive amounts of NOx in response to LPS (35 36 37) . To substantiate the insignificance of immune cells in NOx production during shock, we set up an infectious Salmonella enteritidis model. As reported before (38 , 39) , iNOS–/– mice were more susceptible to Salmonella infection (Fig. 2 A). Since iNOS deficiency in either parenchymal or hematopoietic cells increased susceptibility, both cell types seem to be involved in NO-mediated host defense during salmonellosis (Fig. 2A ). IL-6 and NOx levels were higher in all Salmonella-infected BMT animals (Fig. 2B, C ), indicating increased inflammation due to the irradiation and transplantation procedure. Therefore, we compared systemic NOx levels among BMT mice only. Between 18 to 30 h after infection, significant amounts of circulating NOx were present in Salmonella-infected WT to WT mice (Fig. 2C ), as well as in WT mice with iNOS–/– BM. In contrast, only very low and insignificant levels of NOx were found in chimeric mice with iNOS-negative parenchymal cells (Fig. 2C ). Hence, we conclude that in a bacteremic model of septic shock, there is undoubtedly a predominant role for parenchymal cells in systemic NOx production.


Figure 2
View larger version (34K):
[in this window]
[in a new window]
 
Figure 2. A) Lethality of Salmonella-infected BMT mice. WT, iNOS–/–, and BMT mice were injected ip with 400 cfu S. enteritidis. B and C) IL-6 and NOx levels in serum of Salmonella-infected BMT mice. WT, iNOS–/–, and BMT mice were injected ip with 400 cfu S. enteritidis. Plotted are means ± SD; numbers above bars are number of mice used. ***P < 0.001, **P < 0.01, *P < 0.05, as compared with WT group at a single time point for IL-6 (B) or as indicated for NOx (C). {dagger}Indicates 100% lethality.

Hematopoietic cells are responsible for systemic NOx production during granulomatous inflammation
In an analogous BMT experiment between WT and iNOS–/– mice, we found that hematopoietic cells are solely responsible for systemic NOx production during BCG infection (Fig. 3 ). All mice displayed a substantial enlargement of spleen and liver, which provides evidence that the granulomatous inflammatory reaction is triggered by BCG. Only in mice with a WT parenchymal compartment, an extra TNF challenge caused an additional increase in NOx production (Fig. 3) .


Figure 3
View larger version (17K):
[in this window]
[in a new window]
 
Figure 3. NOx levels in serum of BCG-infected BMT mice. BCG-infected WT, iNOS–/– and BM-transplanted mice were injected iv with PBS or 5 µg TNF. Systemic NOx levels were determined 2 h later. Plotted are means ± SD; numbers above bars are number of mice used. ***P < 0.001, **P < 0.01, as compared with corresponding treatment in WT to WT group.

RNA and protein expression patterns of iNOS
To elucidate the induction pattern of iNOS, we determined the iNOS mRNA levels in various organs via real time-quantitative PCR (Fig. 4 A). It should be noted that the up-regulation of iNOS mRNA can be compared for the various treatments within a single organ only and not between different organs, since organ-specific fluctuations in the expression level of the reference genes influences the relative iNOS mRNA levels. In control mice, minimal traces of iNOS mRNA could be found in lung, spleen, kidney, intestinal tract, and heart. In liver, all three inflammatory stimuli were extremely potent inducers of iNOS expression. In the kidney, iNOS mRNA was found in an approximately equal amount after all three stimuli, and in the heart, a moderate up-regulation of iNOS was also observed. In lung and spleen, BCG was by far the best iNOS inducer, whereas in jejunum and colon, iNOS mRNA was predominantly found after TNF or LPS treatment, respectively.


Figure 4
View larger version (44K):
[in this window]
[in a new window]
 
Figure 4. iNOS mRNA and protein expression pattern. A) Real time-quantitative PCR was performed on RNA extracted 8 (TNF, black bars or LPS, hatched bars) or 2 (BCG, cross-hatched bars) h after challenge. Relative mRNA levels, normalized against mean of 3 reference genes, are shown. Up-regulation of iNOS mRNA is presented as a percentage of the response in PBS (open bars) mice. B) WB analysis. Data shown are from 4 individual experiments. Li: liver; Lu: lung; S: spleen; K: kidney; J: jejunum; C: colon; H: heart.

Because the presence of mRNA is no guarantee for subsequent translation into protein, we also performed WB analysis on organ homogenates. In contrast to mRNA, iNOS protein was never detected in control mice (Fig. 4B ). After BCG infection, a very strong iNOS-specific band was observed in liver, lung, and spleen and a smaller one in kidney and heart (Fig. 4B ), corresponding with the organs in which granulomas could be detected. After TNF or LPS, iNOS protein was always detectable in liver, kidney, jejunum, and colon. In the other organs, however, a very small band was detectable in 50% of the cases. WB on iNOS-deficient organs treated in parallel never showed the iNOS-specific band, as illustrated in Fig. 4B for LPS treatment.

Cellular expression pattern of iNOS via IHC
In control mice, none of the organs stained positive for iNOS (not shown). Identical iNOS expression patterns were observed 8 h after TNF or LPS (Fig. 5 A–H), although less pronounced after LPS, correlating with the systemic NOx levels (Fig. 1) . Positive iNOS staining was detected in hepatocytes, often specifically localized at the canalicular membrane (Fig. 5A, E ). In the kidney, epithelial cells of pelvis (Fig. 5B, F ) and tubuli (not shown) stained positive. Throughout the entire gastrointestinal tract, apical epithelial cells clearly expressed iNOS (Fig. 5C, G ), as well as the paneth cells of the jejunum (Fig. 5D, H ). In addition, after LPS we also observed some iNOS-positive Kupffer cells and occasional granulocytes and/or monocytes in liver, lung, spleen, kidney, and heart (not shown). Nevertheless, despite their ability to express iNOS protein in vivo, our BMT experiments indicate that these WBCs do not contribute significantly to the massive systemic NOx production. Immunohistochemical analysis in LPS-treated iNOS–/– mice with WT BM confirmed this: an occasional granulocyte and/or monocyte stained iNOS-positive (not shown), although no systemic NOx could be detected (Fig. 1B ). Identical results were obtained 16 h after TNF or LPS (not shown).


Figure 5
View larger version (113K):
[in this window]
[in a new window]
 
Figure 5. iNOS-specific IHC. Organs were collected 8 h after 5 µg TNF or 150 µg S. abortus equi LPS, 24 h after 800 cfu of S. enteritidis, or 2 h after PBS in BCG-infected mice. Arrows in A indicate canalicular membranes of hepatocytes. Magnification = x 40 (J, N), x 60 (A, C, E, G), or x 100 (B, D, F, H, I, K, L, M, O, P).

One day after the inoculation of 800 cfu of Salmonella enteritidis, similar iNOS expression patterns were detected as for LPS (Fig. 5I-L ). In addition, some cells of the renal papilla and white pulpa of the spleen also expressed iNOS (not shown). Salmonella infection also occasionally induced some small iNOS-positive granulomas (not shown). Other iNOS-expressing hematopoietic cells were Kupffer cells (Fig. 5I ), cells in the red pulpa of the spleen and granulocytes or monocytes in liver, lung, kidney, and spleen (not shown).

BCG infection induces the formation of larger granulomas, particularly in liver, lung, and spleen, and occasionally in kidney and heart. IHC revealed iNOS expression exclusively in the epithelioid macrophages within those granulomas (Fig. 5M-P ).

Immunostaining of sections derived from iNOS-deficient TNF-, LPS-, Salmonella-, or BCG-treated mice was always negative (not shown). Identical results were obtained with anti-iNOS antibodies from Chemicon and Transduction Laboratories. The use of the anti-iNOS Ab from Santa Cruz Biotechnology was abrogated, because of substantial aspecific binding on sections from iNOS–/– mice (not shown).

DISCUSSION

Increased production of NO has been demonstrated in both experimental and clinical infection, inflammation, and sepsis (9 , 12 , 40 41 42) . Although NO is clearly involved in the development of hypotension during septic shock, many other harmful as well as beneficial effects of NO may play an important role. Some of these dual effects of NO may simply relate to its production by different NOS isoforms. However, also differences in cellular and/or temporal expression patterns might be critical. Systemic NOx production in LPS-treated mice was originally attributed to peritoneal macrophages (35) . Later on it became clear that LPS could also induce (iNOS-derived) NO production in other hematopoietic cells like neutrophils (36) , eosinophils (37) , and lymphocytes (43) . Since both WBCs and NO have important roles in immunity and inflammation (3 , 44) , it was accepted for a long time that WBCs are the main source of systemic NO in infectious and inflammatory diseases, including septic shock. This belief still generally prevails, despite the fact that also a wide range of parenchymal cells, such as hepatocytes, epithelial, vascular smooth muscle, and endothelial cells have the ability to express iNOS, both in vitro after LPS and/or cytokine stimulation (25 , 26 , 45 46 47) , as well as in vivo during endotoxic and/or septic shock (26 27 28 29 30 , 48) . Moreover, despite the fact that LPS-treated Tyk2–/– macrophages are unable to produce NO, identical NO levels can be found in circulation of endotoxic Tyk2–/– and WT mice, already suggesting that systemic LPS-induced NO does not originate from macrophages (49) . More recently, LPS treatment of iNOS-chimeric mice indicated that indeed parenchymal cells are the most important source of iNOS during endotoxemia (22) . However, these results were not confirmed in an infectious shock model, which is not only clinically more relevant, but may also affect circulating hematopoietic cells to a much greater extent than LPS. In addition, the cellular source of parenchymal iNOS was not determined (ND). In our study, we found that even in an infectious and lethal septic shock model, the hematopoietic cell population does not contribute significantly to systemic NO production. We also identified iNOS-expressing hepatocytes, paneth cells, and epithelial cells of the gut and kidney as the parenchymal source of systemic NO after TNF, LPS or S. enteritidis challenge. NO produced by hepatocytes and paneth cells can easily reach the circulation via sinusoids and intestinal venules, respectively. Apical intestinal epithelium produces NO that is likely to diffuse into the intestinal lumen. Still, intestinal villi contain a complex network of blood vessels designed to absorb nutrients from the lumen, making it possible for NO to reach the blood via this way. Since liver and intestinal tract represent two of the largest organs within the mammalian body, they correspond to a vast amount of iNOS-expressing cells.

iNOS-expressing hepatocytes, Kupffer cells, and gastro-intestinal epithelial cells have been described in endotoxic (26, 28–30, 50) and bacteremic (51) rodents. Also the specific canalicular staining pattern for iNOS within hepatocytes has been observed before (50) . Interestingly, we also found distinctive iNOS expression in paneth cells during TNF, LPS, or bacterial inflammation, which has never been reported before. It is not until recently that great interest arose for these important cells of innate mucosal immunity. Several antimicrobial peptides and proteins are released by paneth cells on LPS challenge (52 , 53) . The well-defined function of iNOS-derived NO in innate immunity (3) makes iNOS induction in paneth cells very plausible.

As evidenced by our immunohistochemical study and that of others (28 29 30 , 54) , LPS treatment of rodents induces the expression of iNOS in monocytes, in infiltrated and resident macrophages, and in granulocytes. However, and surprisingly, those cells do not contribute significantly to systemic NO production, as demonstrated by our BMT experiments. Several possible explanations may be envisioned. It could be that those few cells are simply insufficient to contribute significantly. Other explanations could be that the NO is locally captured in a rapid reaction like that with other radicals or that iNOS expression in these WBCs does not correlate with NO production. Indeed, when L-arg is limited, for example, iNOS produces superoxide rather than NO in a so-called "uncoupled " reaction (55) . It has also been reported that in an inflammatory setting, WBCs produce NO only after engagement with integrins and therefore need to infiltrate into tissue first (56 , 57) .

In contrast to rodents, human macrophage cell lines are incapable of inducing iNOS activity in response to LPS, not even in combination with cytokines (57 58 59) . Moreover, iNOS activity can hardly be detected in macrophages isolated from septic patients (60 61 62) . Nevertheless, in both species, systemic NO levels are elevated during infection, inflammation, and septic shock. It has always been believed that this discrepancy could be attributed to an inherent difference between mice and men. However, our data indicate that the role of monocytes/macrophages as the source of shock-inducing NO is much less prominent than generally assumed. This is further supported by a study of Clark and colleagues (63) , which clearly shows parenchymal iNOS expression in human malaria and sepsis.

Whereas parenchymal cells are the major source of systemic NOx during TNF-, LPS- or Salmonella-induced shock, hematopoietic cells represent the main source of systemic NOx during BCG infection. IHC revealed the epithelioid macrophages of the BCG-induced granulomas as the only iNOS source, which is in correspondence with previous data obtained from Mycobacterium-infected rodents and men (64 65 66) . In addition, during other intracellular infectious diseases such as Leishmania, Listeria, or Toxoplasma infection, the expression of iNOS is restricted to the hematopoietic lineage (67 68 69) .

In conclusion, our in vivo study revealed a differential role for hematopoietic cells in systemic NO production. Although hematopoietic cells are crucial for the production of systemic NO during granulomatous inflammation, they do not contribute at all to the production of circulating NO after systemic TNF or LPS challenge. In addition, in a bacteremic model of septic shock, cells of hematopoietic origin did not significantly add to the enormous systemic NO production. Instead, hepatocytes, paneth cells, and epithelial cells of gut and kidney represent the parenchymal source of systemic NO. Interestingly, our data also suggest that differences between in vitro and in vivo observations, rather than species diversities, might be responsible for the long-standing contradiction between the significant amounts of systemic NO detectable in a wide range of human inflammatory diseases vs. the inability of human monocytes/macrophages to produce NO in vitro (70 , 71) .

ACKNOWLEDGMENTS

The authors thank Linda Van Geert, Joris De Backer, and Geert Versporten for animal care; Dr. H. Bluethmann (Roche, Basel) for the generous gift of TNF-R1–/– mice; and Dr. C. Cuvelier for discussions about histology. This research was supported by grants from the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, the Interuniversity Attraction Pole program and Universiteit Gent-Geconcerteerde Onderzoeks Acties.

Received for publication February 3, 2006. Accepted for publication June 23, 2006.

REFERENCES

  1. Bateman, R. M., Sharpe, M. D., Ellis, C. G. (2003) Bench-to-bedside review: microvascular dysfunction in sepsis–hemodynamics, oxygen transport, and nitric oxide. Crit. Care 7,359-373[CrossRef][Medline]
  2. Stuehr, D. J. (1999) Mammalian nitric oxide synthases. Biochim. Biophys. Acta 1411,217-230[Medline]
  3. Bogdan, C. (2001) Nitric oxide and the immune response. Nat. Immunol. 2,907-916[CrossRef][Medline]
  4. Coleman, J. W. (2001) Nitric oxide in immunity and inflammation. Int. Immunopharmacol. 1,1397-1406[CrossRef][Medline]
  5. Colasanti, M., Suzuki, H. (2000) The dual personality of NO. Trends Pharmacol. Sci. 21,249-252[CrossRef][Medline]
  6. Kilbourn, R. G., Gross, S. S., Jubran, A., Adams, J., Griffith, O. W., Levi, R., Lodato, R. F. (1990) NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 87,3629-3632[Abstract/Free Full Text]
  7. Peschon, J. J., Torrance, D. S., Stocking, K. L., Glaccum, M. B., Otten, C., Willis, C. R., Charrier, K., Morrissey, P. J., Ware, C. B., Mohler, K. M. (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160,943-952[Abstract/Free Full Text]
  8. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., Bluethmann, H. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364,798-802[CrossRef][Medline]
  9. Cauwels, A., Van Molle, W., Janssen, B., Everaerdt, B., Huang, P., Fiers, W., Brouckaert, P. (2000) Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity 13,223-231[CrossRef][Medline]
  10. Cauwels, A., Bultinck, J., Brouckaert, P. (2005) Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress. Cell Mol. Life Sci. 62,1632-1640[CrossRef][Medline]
  11. Sands, K. E., Bates, D. W., Lanken, P. N., Graman, P. S., Hibberd, P. L., Kahn, K. L., Parsonnet, J., Panzer, R., Orav, E. J., Snydman, D. R., et al (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 278,234-240[Abstract]
  12. Feihl, F., Waeber, B., Liaudet, L. (2001) Is nitric oxide overproduction the target of choice for the management of septic shock?. Pharmacol. Ther. 91,179-213[CrossRef][Medline]
  13. Thiemermann, C. (1997) Nitric oxide and septic shock. Gen. Pharmacol. 29,159-166[Medline]
  14. Ceppi, E. D., Smith, F. S., Titheradge, M. A. (1997) Nitric oxide, sepsis and liver metabolism. Biochem. Soc. Trans. 25,929-934[Medline]
  15. Knowles, R. G., Moncada, S. (1992) Nitric oxide as a signal in blood vessels. Trends Biochem. Sci. 17,399-402[CrossRef][Medline]
  16. Kilbourn, R. G., Traber, D. L., Szabo, C. (1997) Nitric oxide and shock. Dis. Mon. 43,277-348[Medline]
  17. Johnson, M. L., Billiar, T. R. (1998) Roles of nitric oxide in surgical infection and sepsis. World J. Surg. 22,187-196[CrossRef][Medline]
  18. Avontuur, J. A., Tutein Nolthenius, R. P., van Bodegom, J. W., Bruining, H. A. (1998) Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. 26,660-667[CrossRef][Medline]
  19. Lopez, A., Lorente, J. A., Steingrub, J., Bakker, J., McLuckie, A., Willatts, S., Brockway, M., Anzueto, A., Holzapfel, L., Breen, D., et al (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32,21-30[CrossRef][Medline]
  20. Laubach, V. E., Foley, P. L., Shockey, K. S., Tribble, C. G., Kron, I. L. (1998) Protective roles of nitric oxide and testosterone in endotoxemia: evidence from NOS-2-deficient mice. Am. J. Physiol. 275,2211-2218
  21. Andrew, P. J., Mayer, B. (1999) Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 43,521-531[Abstract/Free Full Text]
  22. Hickey, M. J., Sihota, E., Amrani, A., Santamaria, P., Zbytnuik, L. D., Ng, E. S., Ho, W., Sharkey, K. A., Kubes, P. (2002) Inducible nitric oxide synthase (iNOS) in endotoxemia: chimeric mice reveal different cellular sources in various tissues. FASEB J. 16,1141-1143[Abstract/Free Full Text]
  23. Poon, B. Y., Raharjo, E., Patel, K. D., Tavener, S., Kubes, P. (2003) Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation 108,1107-1112[Abstract/Free Full Text]
  24. Veihelmann, A., Hofbauer, A., Krombach, F., Dorger, M., Maier, M., Refior, H. J., Messmer, K. (2002) Differential function of nitric oxide in murine antigen-induced arthritis. Rheumatology 41,509-517[Abstract/Free Full Text]
  25. Nussler, A. K., Geller, D. A., Sweetland, M. A., Di Silvio, M., Billiar, T. R., Madariaga, J. B., Simmons, R. L., Lancaster, J. R., Jr (1993) Induction of nitric oxide synthesis and its reactions in cultured human and rat hepatocytes stimulated with cytokines plus LPS. Biochem. Biophys. Res. Commun. 194,826-835[CrossRef][Medline]
  26. Geller, D. A., Di Silvio, M., Nussler, A. K., Wang, S. C., Shapiro, R. A., Simmons, R. L., Billiar, T. R. (1993) Nitric oxide synthase expression is induced in hepatocytes in vivo during hepatic inflammation. J. Surg. Res. 55,427-432[CrossRef][Medline]
  27. Knowles, R. G., Merrett, M., Salter, M., Moncada, S. (1990) Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem. J. 270,833-836[Medline]
  28. Sato, K., Miyakawa, K., Takeya, M., Hattori, R., Yui, Y., Sunamoto, M., Ichimori, Y., Ushio, Y., Takahashi, K. (1995) Immunohistochemical expression of inducible nitric oxide synthase (iNOS) in reversible endotoxic shock studied by a novel monoclonal antibody against rat iNOS. J. Leukoc. Biol. 57,36-44[Abstract]
  29. Buttery, L. D., Evans, T. J., Springall, D. R., Carpenter, A., Cohen, J., Polak, J. M. (1994) Immunochemical localization of inducible nitric oxide synthase in endotoxin-treated rats. Lab. Invest. 71,755-764[Medline]
  30. Cook, H. T., Bune, A. J., Jansen, A. S., Taylor, G. M., Loi, R. K., Cattell, V. (1994) Cellular localization of inducible nitric oxide synthase in experimental endotoxic shock in the rat. Clin. Sci. 87,179-186[Medline]
  31. Laubach, V. E., Shesely, E. G., Smithies, O., Sherman, P. A. (1995) Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. U. S. A. 92,10688-10692[Abstract/Free Full Text]
  32. Van Snick, J., Cayphas, S., Vink, A., Uyttenhove, C., Coulie, P. G., Rubira, M. R., Simpson, R. J. (1986) Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. U. S. A. 83,9679-9683[Abstract/Free Full Text]
  33. Green, L. C., Wagner, D. A., Glogowski, J., Skipper, P. L., Wishnok, J. S., Tannenbaum, S. R. (1982) Analysis of nitrate, nitrite, and (15N)nitrate in biological fluids. Anal. Biochem. 126,131-138[CrossRef][Medline]
  34. Cauwels, A., Brouckaert, P., Grooten, J., Huang, S., Aguet, M., Fiers, W. (1995) Involvement of IFN-gamma in Bacillus Calmette-Guerin-induced but not in tumor-induced sensitization to TNF-induced lethality. J. Immunol. 154,2753-2763[Abstract]
  35. Stuehr, D. J., Marletta, M. A. (1985) Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 82,7738-7742[Abstract/Free Full Text]
  36. Kolls, J., Xie, J., LeBlanc, R., Malinski, T., Nelson, S., Summer, W., Greenberg, S. S. (1994) Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. Proc. Soc. Exp. Biol. Med. 205,220-229[Abstract]
  37. Oliveira, S. H., Fonseca, S. G., Romao, P. R., Figueiredo, F., Ferreira, S. H., Cunha, F. Q. (1998) Microbicidal activity of eosinophils is associated with activation of the arginine-NO pathway. Parasite Immunol. 20,405-412[CrossRef][Medline]
  38. Alam, M. S., Akaike, T., Okamoto, S., Kubota, T., Yoshitake, J., Sawa, T., Miyamoto, Y., Tamura, F., Maeda, H. (2002) Role of nitric oxide in host defense in murine salmonellosis as a function of its antibacterial and antiapoptotic activities. Infect. Immun. 70,3130-3142[Abstract/Free Full Text]
  39. Mastroeni, P., Vazquez-Torres, A., Fang, F. C., Xu, Y., Khan, S., Hormaeche, C. E., Dougan, G. (2000) Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J. Exp. Med. 192,237-248[Abstract/Free Full Text]
  40. Lai, C. S., Komarov, A. M. (1994) Spin trapping of nitric oxide produced in vivo in septic-shock mice. FEBS Lett. 345,120-124[CrossRef][Medline]
  41. Evans, T., Carpenter, A., Kinderman, H., Cohen, J. (1993) Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ. Shock 41,77-81[Medline]
  42. Tracey, W. R., Tse, J., Carter, G. (1995) Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J. Pharmacol. Exp. Ther. 272,1011-1015[Abstract/Free Full Text]
  43. Victor, V. M., Rocha, M., De la Fuente, M. (2003) N-acetylcysteine protects mice from lethal endotoxemia by regulating the redox state of immune cells. Free Radic. Res. 37,919-929[CrossRef][Medline]
  44. Arkovitz, M. S., Wispe, J. R., Garcia, V. F., Szabo, C. (1996) Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J. Pediatr. Surg. 31,1009-1015[CrossRef][Medline]
  45. Asano, K., Chee, C. B., Gaston, B., Lilly, C. M., Gerard, C., Drazen, J. M., Stamler, J. S. (1994) Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 91,10089-10093[Abstract/Free Full Text]
  46. Robertson, D. A., Hughes, G. A., Lyles, G. A. (2004) Expression of inducible nitric oxide synthase in cultured smooth muscle cells from rat mesenteric lymphatic vessels. Microcirculation 11,503-515[CrossRef][Medline]
  47. Wu, F., Cepinskas, G., Wilson, J. X., Tyml, K. (2001) Nitric oxide attenuates but superoxide enhances iNOS expression in endotoxin- and IFNgamma-stimulated skeletal muscle endothelial cells. Microcirculation 8,415-425[CrossRef][Medline]
  48. Hoffman, R. A., Zhang, G., Nussler, N. C., Gleixner, S. L., Ford, H. R., Simmons, R. L., Watkins, S. C. (1997) Constitutive expression of inducible nitric oxide synthase in the mouse ileal mucosa. Am. J. Physiol. 272,G383-392[Medline]
  49. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., et al (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13,549-560[CrossRef][Medline]
  50. Vos, T. A., Gouw, A. S., Klok, P. A., Havinga, R., van Goor, H., Huitema, S., Roelofsen, H., Kuipers, F., Jansen, P. L., Moshage, H. (1997) Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 113,1323-1333[CrossRef][Medline]
  51. Parmely, M. J., Wang, F., Wright, D. (2001) Gamma interferon prevents the inhibitory effects of oxidative stress on host responses to Escherichia coli infection. Infect. Immun. 69,2621-2629[Abstract/Free Full Text]
  52. Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., Ouellette, A. J. (2000) Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 1,113-118[Medline]
  53. Ayabe, T., Satchell, D. P., Pesendorfer, P., Tanabe, H., Wilson, C. L., Hagen, S. J., Ouellette, A. J. (2002) Activation of Paneth cell alpha-defensins in mouse small intestine. J. Biol. Chem. 277,5219-5228[Abstract/Free Full Text]
  54. Stumm, M. M., D’Orazio, D., Sumanovski, L. T., Martin, P. Y., Reichen, J., Sieber, C. C. (2002) Endothelial, but not the inducible, nitric oxide synthase is detectable in normal and portal hypertensive rats. Liver 22,441-450[CrossRef][Medline]
  55. Xia, Y., Roman, L. J., Masters, B. S., Zweier, J. L. (1998) Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273,22635-22639[Abstract/Free Full Text]
  56. Miles, A. M., Owens, M. W., Milligan, S., Johnson, G. G., Fields, J. Z., Ing, T. S., Kottapalli, V., Keshavarzian, A., Grisham, M. B. (1995) Nitric oxide synthase in circulating vs. extravasated polymorphonuclear leukocytes. J. Leukoc. Biol. 58,616-622[Abstract]
  57. Weinberg, J. B., Misukonis, M. A., Shami, P. J., Mason, S. N., Sauls, D. L., Dittman, W. A., Wood, E. R., Smith, G. K., McDonald, B., Bachus, K. E., et al (1995) Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86,1184-1195[Abstract/Free Full Text]
  58. Jungi, T. W., Adler, H., Adler, B., Thony, M., Krampe, M., Peterhans, E. (1996) Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. Vet. Immunol. Immunopathol. 54,323-330[CrossRef][Medline]
  59. Arias, M., Zabaleta, J., Rodriguez, J. I., Rojas, M., Paris, S. C., Garcia, L. F. (1997) Failure to induce nitric oxide production by human monocyte-derived macrophages. Manipulation of biochemical pathways. Allergol. Immunopathol. (Madr). 25,280-288[Medline]
  60. Hersch, M., Scott, J. A., Izbicki, G., McCormack, D., Cepinkas, G., Ostermann, M., Sibbald, W. J. (2005) Differential inducible nitric oxide synthase activity in circulating neutrophils vs. mononuclears of septic shock patients. Intensive Care Med. 31,1132-1135[CrossRef][Medline]
  61. Kobayashi, A., Hashimoto, S., Kooguchi, K., Kitamura, Y., Onodera, H., Urata, Y., Ashihara, T. (1998) Expression of inducible nitric oxide synthase and inflammatory cytokines in alveolar macrophages of ARDS following sepsis. Chest 113,1632-1639[Medline]
  62. Annane, D., Sanquer, S., Sebille, V., Faye, A., Djuranovic, D., Raphael, J. C., Gajdos, P., Bellissant, E. (2000) Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 355,1143-1148[CrossRef][Medline]
  63. Clark, I. A., Awburn, M. M., Whitten, R. O., Harper, C. G., Liomba, N. G., Molyneux, M. E., Taylor, T. E. (2003) Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar. J. 2,6[CrossRef][Medline]
  64. Ehlers, S., Kutsch, S., Benini, J., Cooper, A., Hahn, C., Gerdes, J., Orme, I., Martin, C., Rietschel, E. T. (1999) NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 98,313-323[CrossRef][Medline]
  65. MacMicking, J. D., North, R. J., LaCourse, R., Mudgett, J. S., Shah, S. K., Nathan, C. F. (1997) Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 94,5243-5248[Abstract/Free Full Text]
  66. Schon, T., Elmberger, G., Negesse, Y., Pando, R. H., Sundqvist, T., Britton, S. (2004) Local production of nitric oxide in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 8,1134-1137[Medline]
  67. Schluter, D., Kaefer, N., Hof, H., Wiestler, O. D., Deckert-Schluter, M. (1997) Expression pattern and cellular origin of cytokines in the normal and Toxoplasma gondii-infected murine brain. Am. J. Pathol. 150,1021-1035[Abstract]
  68. Stenger, S., Thuring, H., Rollinghoff, M., Bogdan, C. (1994) Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180,783-793[Abstract/Free Full Text]
  69. Jungi, T. W., Pfister, H., Sager, H., Fatzer, R., Vandevelde, M., Zurbriggen, A. (1997) Comparison of inducible nitric oxide synthase expression in the brains of Listeria monocytogenes-infected cattle, sheep, and goats and in macrophages stimulated in vitro. Infect. Immun. 65,5279-5288[Abstract]
  70. Denis, M. (1994) Human monocytes/macrophages: NO or no NO?. J. Leukoc. Biol. 55,682-684[Abstract]
  71. Albina, J. E. (1995) On the expression of nitric oxide synthase by human macrophages. Why no NO?. J. Leukoc. Biol. 58,643-649[Abstract]



This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
Y. Chen, C. S. K. Kam, F. Q. Liu, Y. Liu, V. C. H. Lui, J. R. Lamb, and P. K. H. Tam
LPS-induced up-regulation of TGF-{beta} receptor 1 is associated with TNF-{alpha} expression in human monocyte-derived macrophages
J. Leukoc. Biol., May 1, 2008; 83(5): 1165 - 1173.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Kumar, L. D. Hazlett, and F.-S. X. Yu
Flagellin Suppresses the Inflammatory Response and Enhances Bacterial Clearance in a Murine Model of Pseudomonas aeruginosa Keratitis
Infect. Immun., January 1, 2008; 76(1): 89 - 96.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Hasselblatt, M. Rath, V. Komnenovic, K. Zatloukal, and E. F. Wagner
Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase
PNAS, October 23, 2007; 104(43): 17105 - 17110.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. Wu, N. Gokden, and P. R. Mayeux
Evidence for the Role of Reactive Nitrogen Species in Polymicrobial Sepsis-Induced Renal Peritubular Capillary Dysfunction and Tubular Injury
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1807 - 1815.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Summary
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
fj.06-5798fjev1
20/13/2363    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bultinck, J.
Right arrow Articles by Cauwels, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bultinck, J.
Right arrow Articles by Cauwels, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS